Skip to main content
. 2019 Dec 2;9:18021. doi: 10.1038/s41598-019-54226-7

Figure 8.

Figure 8

VEGF binding properties as measured by SPR. Sensorgrams showing the binding profiles to immobilized VEGF (~300 RU) for (a) ranibizumab (800 nM), (b) aflibercept (100 nM), and (c) bevacizumab (100 nM) at D0 (black dotted line) and D7 (blue). For each injection n = 6. The binding profiles (RU) have been normalized to baseline and the blank values subtracted.